Presidio Medical™ Announces Executive Appointment
March 21 2023 - 7:51PM
Business Wire
Presidio Medical, Inc., a clinical-stage medical device company
developing a transformational Ultra Low Frequency (ULF™)
neuromodulation platform, announced that Scott Salys joined the
Executive Team as Chief Research & Development and Operations
Officer. Mr. Salys is a 25-year veteran in Class III active
implantable devices leading R&D, Operations, Supply Chain,
Program Management, and Durable Medical Equipment (DME)
organizations. Mr. Salys joins Presidio from Abbott where he was
most recently the Divisional Vice President of R&D of the Heart
Failure business.
“We are thrilled to have someone with Scott’s breadth of
experience across Operations, Supply Chain, and R&D join the
Presidio team. Not only does Scott have functional expertise in key
areas for Presidio’s progression, but he has managed several
business lines within cardiac rhythm management and
neuromodulation, which is complimentary to the platform Presidio is
building,” said Michael Onuscheck, Chairman and CEO of Presidio
Medical.
“I am excited to join this incredibly talented team and lead
Presidio Medical through the next stage of clinical and product
development. We have the unique opportunity to create
neuromodulation therapies for new patient populations as well as
transform conventional neuromodulation therapy. I am passionate
about building high-performing teams and look forward to delivering
our novel ULF platform to patients,” said Mr. Salys.
Prior to joining Presidio Medical, Mr. Salys was the Divisional
Vice President of R&D (2021 to 2022) and Divisional Vice
President of Operations (2017 to 2021) in Abbott’s Heart Failure
business, where he led the organization through a phase of rapid
growth and expansion. In addition to roles in R&D and
Operations, Mr. Salys transformed the Heart Failure DME business by
shifting strategy, building the team, and establishing a commercial
organization that delivered triple digit growth. Mr. Salys also
served on Abbott’s Executive Crisis Management Team, Scientific
Governing Board, as well as the Board of Directors for Abbott
Global Enterprises.
Prior to Abbott’s acquisition of St. Jude Medical (SJM) in 2017,
Mr. Salys spent over 16 years at SJM in R&D, Operations, and
Supply Chain roles across various divisions and geographies.
Scott’s most recent roles at SJM included Vice President of
Operations and R&D, VP of Supply Chain, VP of Operations, and
VP of Program Management. Mr. Salys successfully integrated newly
acquired businesses, strengthened global organizations, executed
change management initiatives, and delivered rapid growth in the
neuromodulation and cardiac resynchronization therapy markets.
ABOUT PRESIDIO MEDICAL
Presidio Medical was founded in 2017 and is headquartered in
South San Francisco, CA. The clinical-stage, privately held medical
device company is developing a transformational neuromodulation
platform to treat diseases of undesired neural activity with a
first indication in the treatment of chronic pain. Presidio’s
current investors include Invus Opportunities and Action Potential
Venture Capital. For more information, visit
www.presidiomedical.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230321006015/en/
Presidio Medical, Inc. media@presidiomedical.com
650-502-1071